AtriCure (ATRC) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
AtriCure Inc. (ATRC) PT Raised to $26 at Needham & Company Following 2Q Beat
July 28, 2017 8:07 AM EDTNeedham & Company raised its price target on AtriCure Inc. (NASDAQ: ATRC) to $26.00 (from $25.00) while maintaining a Buy rating following the company's 2Q. Revenue was $45.2M vs. consensus of $44.2M, EBITDA was ($0.4M) vs. consensus of ($1.9M), and EPS was ($0.21) vs. consensus of ($0.26).
For... More
